To the editor:
The breast and ovarian cancer susceptibility gene BRCA1 has been extensively investigated for its biological function and potential for targeted therapy. Cell lines derived from human tissues have been employed as research reagents in such studies, and one of those most commonly used is the breast cancer cell line MCF-7. Recently, the notion that MCF-7 carries a hemizygous wild-type allele of BRCA1 has been referred to in a growing number of research articles [1] [2] [3] [4] [5] [6] [7] [8] [9] , with some studies fundamentally based upon this concept. This idea seems to originate from an article published in 1996 by Holt et al. [10] . In the article, Holt et al. noted that MCF-7 has only one allele at each of seven polymorphic DNA markers encompassing the BRCA1 gene locus, indicating genomic loss of one copy of the 2 Mb region containing BRCA1. This description implies that MCF-7 carries only one copy of the BRCA1 gene and seemingly has been interpreted as such in subsequent publications.
In agreement with Holt et al., recent data from GenomeWide Human Single-Nucleotide Polymorphism (SNP) Array 6.0 analysis at the Wellcome Trust Sanger Institute (http://www.sanger.ac.uk/genetics/CGP/) revealed loss of heterozygosity (LOH) at the BRCA1 gene locus at chromosome 17q21.31 in MCF-7. However, in contrast to the above-mentioned interpretation, these SNP array data suggest the presence of two copies of the BRCA1 gene in MCF-7, with a normalized absolute copy number score 1.93 ± 0.41 (mean ± SD) at the markers within the BRCA1 gene locus as calculated by Sanger Institute's PICNIC algorithm. In addition, we conducted a fluorescence in situ hybridization (FISH) analysis of the BRCA1 gene locus using RP11-242D8, a BAC probe overlapping with the BRCA1 5 0 region. This assay was performed with two strains of MCF-7 cell line independently grown at distinct institutions (termed MCF-7-J maintained at Johns Hopkins University, and MCF-7-A at Aichi Cancer Center Research Institute), and demonstrated that the modes of the BRCA1 gene copy number in two strains were four and three, respectively (Fig. 1a, b ; Table 1 ). The same FISH result was obtained using another BAC probe, RP11-948G15, which was assigned at a close proximity to the 3 0 end of BRCA1 (data not shown). The clonal variation between separate cultures of MCF-7 observed in our study is consistent with previous studies by others conducting spectral karyotype (SKY) analysis with MCF-7 [11] [12] [13] . Overall, MCF-7 cells were revealed to have multiple copies of BRCA1 despite the apparent LOH of the corresponding genomic region. This allelotype is generally considered to occur when one of the two alleles is initially deleted, and the remaining allele is subsequently duplicated. Holt et al. [10] additionally stated that another breast cancer cell line MDA-MB-157 was also subjected to genomic loss of one copy of the 2 Mb region containing BRCA1. Similar to MCF-7, however, SNP array 6.0 data at the Sanger Institute indicates a copy number score 1.78 ± 0.33 (mean ± SD) at the BRCA1 locus, suggesting that MDA-MB-157 has two copies of the BRCA1 gene, although it also suggests LOH of the entire chromosome 17 in this cell line. Our FISH analysis suggested the presence of two major cell populations within our MDA-MB-157 culture, which carry two and four copies of BRCA1, respectively ( Fig. 1c ; Table 1 ). These results are again consistent with previous reports describing the karyotypic heterogeneity of MDA-MB-157 cell line [11, 12] .
Collectively, these findings indicate that MCF-7 and MDA-MB-157 carry multiple copies of the BRCA1 gene. Since the majority of cancer cells exhibit a chromosomal instability phenotype in which chromosomes are actively gained and lost, it should be noted that LOH does not necessarily mean the reduction of copy number at the corresponding genomic locus, particularly in cancer cells.
